The ARV-825, a PROTAC molecule with BRD4-binding OTX015 warhead and CRBN E3 ligase recruiter, was stably formulated with PEG-PLGA into nanoparticles, which improved the blood half-life and passive tumor targetability of the PROTAC. This evidence concerns the gene BRD4 and neoplasm.